Immunogenicity of Different Primary Immunization Schedules with Inactivated Poliovirus Vaccine (IPV) Plus Pentavalent Vaccine (DTwP-HBV-Hib) or with Hexavalent Vaccine (DTwP-HBV-Hib-IPV)

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

1,190

Participants

Timeline

Start Date

January 28, 2025

Primary Completion Date

December 30, 2027

Study Completion Date

December 30, 2027

Conditions
Polio
Interventions
BIOLOGICAL

Pentavalent vaccine

Whole-cell pertussis pentavalent vaccine (wP-Penta): Each 0.5 ml dose contains diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen, Haemophilus influenzae type b conjugate

BIOLOGICAL

Hexavalent vaccine

Whole-cell pertussis hexavalent vaccine (wP-Hexa): Each 0.5 ml dose contains diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen, Haemophilus influenzae type b conjugate, and inactivated polioviruses to all three poliovirus types: type 1 , 2 and 3

BIOLOGICAL

Inactivated poliovirus vaccine (IPV)

one dose of IPV (0.5 mL) contains inactivated polioviruses to all three poliovirus types: type 1, 2 and 3

BIOLOGICAL

Bivalent oral polio vaccine (bOPV)

Contain two poliovirus types: type 1 and 3

BIOLOGICAL

Fractional IPV( fIPV)

The dose of fIPV is 0.1 mL or 1/5th of a full dose

All Listed Sponsors
lead

International Centre for Diarrhoeal Disease Research, Bangladesh

OTHER